Mismatch negativity is not correlated with neuroendocrine indicators of catecholaminergic activity in healthy subjects

Human Psychopharmacology

Volumn 18, Issue 3, 2003, Pages 201-205

  Hansenne, M ^a   Pinto, E ^a   Scantamburlo, G ^a   Couvreur, A ^a   Reggers, J ^a   Fuchs, S ^a   Pitchot, W ^a   Ansseau, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Dopamine; MMN; Noradrenaline; Pharmacology; Psychobiology

Indexed keywords

APOMORPHINE; ATIPAMEZOLE; CHLORPHENIRAMINE; CLONIDINE; CLOZAPINE; GROWTH HORMONE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NEUROTRANSMITTER; NITROUS OXIDE; TRIAZOLAM; VASOPRESSIN;

ADULT; AREA UNDER THE CURVE; AUDITORY CORTEX; BRAIN FUNCTION; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; MISMATCH NEGATIVITY; NEUROENDOCRINE SYSTEM; NEUROMODULATION; NORADRENERGIC SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SCALP;

ACOUSTIC STIMULATION; ADULT; APOMORPHINE; BRAIN; CLONIDINE; CONTINGENT NEGATIVE VARIATION; DOPAMINE; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; NOREPINEPHRINE;

EID: 0038753933     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.468     Document Type: Review

References (35)

1. Ansseau M, Von Frenckell R, Cerfontaine J-L, et al. 1988. Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry 153: 65-71.
2. Born J, Pietrowsky R, Fehn HL. 1998. Neuropsychological effects of vasopressin in healthy humans. Progr Brain Res 119: 619-1943.
3. Bray GA. 1978. Definition, measurement, and classification of the syndromes of obesity. Int J Obesity 2: 99-112.
4. Catts SV, Shelley AM, Ward PB, et al. 1995. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am J Psychiatry 152: 213-219.
5. Checkley SA, Slade AP, Shur E. 1981. Growth hormone and other responses to clonidine in patients with endogenous depression. Br J Psychiatry 138: 51-55.
6. Hansenne M, Pitchot W, Gonzalez Moreno A, Von Frenckell R, Ansseau M. 1992. Clonidine test and MMPI scales in major depression. Eur Psychiatry 7: 129-133.
7. Hirvonen J, Jaaskelainen IP, Näädsanen R, Sillanaukke P. 2000. Adenosine A1/A2a receptors mediate suppression of mismatch negativity by ethanol in humans. Neuroscience Lett 278: 57-60.
8. Jaaskelainen IP, Hirvonen J, Kujala T, et al. 1998. Effect of naltrexone and ethanol on auditory event-related brain potentials. Alcohol 15: 105-111.
9. Javitt DC. 2000. Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol Neuro-Otol 5: 207-215.
10. Javitt DC, Doneshka P, Grochowski S, Ritter W. 1995. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 52: 550-558.
11. Javitt DC, Grochowski S, Shelley AM, Ritter W. 1997. Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/interdeviant interval. Electroencephalography Clin Neurophysiol 108: 143-153.
12. Lal S, De La Vega SE, Sourkes TL, Friesen HG. 1972. Effect of apo-morphine in human growth hormone secretion. Lancet ii: 661.
13. Matussek N, Ackenheil M, Hippius H, et al. 1980. Effect of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res 2: 25-36.
14. Mervaala E, Alhainen K, Helkala EL, et al. 1993. Electrophysiological and neuropsychological effects of a central alpha-2 antagonist atipamezole in healthy volunteers. Behav Brain Res 55: 85-91.
15. Mitchell PB, Bearn JA, Corn TH, Checkley SA. 1988. Growth hormone response to clonidine after recovery in patients with endogenous depression. Br J Psychiatry 152: 34-38.
16. Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP. 1995. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology 20: 365-375.
17. Näädsanen R. 1990. The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav Brain Sci 13: 201-288.
18. Näätänen R. 1995. The mismatch negativity - A powerful tool for cognitive neuroscience. Ear Hearing 16: 6-18.
19. Näädsanen R. 2001. The perception of speech sounds by the human brain as reflected by the mismatch negativity (MMN) and its magnetic equivalent (MMNm). Psychophysiology 38: 1-21.
20. Näädsanen R, Gaillard AWK, Mantysalo S. 1978. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol 42: 313-329.
21. Nakagome K, Ichikawa I, Kanno O, et al. 1998. Overnight effects of triazomal on cognitive function: an event-related potentials study. Neuropsychobiology 38: 232-240.
22. Oades RD, Dittmann-Balcar A, Zerbin D, Grzella I. 1997. Impaired attention-dependent augmentation of MMN in nonparanoid vs paranoid schizophrenic patients: a comparison with obsessive-compulsive disorder and healthy subjects. Biol Psychiatry 41: 1196-1210.
23. Oranje B, van Berckel BN, Kemmer C, van Ree JM, Kahn RS, Verbaten MN. 2000. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22: 293-302.
24. Pang EW, Fowler B. 1999. Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide. Psychophysiology 36: 552-558.
25. Picton TW, Alain C, Otten L, Ritter W, Achim A. 2000. Mismatch negativity: different water in the same river. Audiol Neuro-Otol 5: 111-139.
26. Pitchot W, Hansenne M, Gonzalez Moreno A, Ansseau M. 1992. Suicidal behavior and growth hormone response to apomorphine test. Biol Psychiatry 31: 1213-1219.
27. Serra JM, Escera C, Sanchez-Turet M, Sanchez-Sastre J, Grau C. 1996. The H1-receptor antagonist chlorpheniramine decreases the ending phase of the mismatch negativity of the human auditory event-related potentials. Neurosci Lett 203: 77-80.
28. Solanto MV 1998. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review. Behav Brain Res 94: 127-152.
29. Sourkes TL, Lal S. 1975. Apomorphine and its relation to dopamine in the nervous system. In Advances in Neurochemistry, Agranoff BW, Aprison MH (eds). Raven Press: New York; 247-299.
30. Thomas AE, McKay DA, Cutlip MB. 1976. A monograph method for assessing body weight. Am J Clin Nutr 29: 302-304.
31. Trestman RL, Coccaro, EF, Lawrence T, Knott P, Gabriel SM, Siever LJ. 1994. The stability of plasma growth hormone and MHPG responses to repeated clonidine challenge in normal males. Psychoneuroendocrinology 19: 13-20.
32. Tulandi T, Lal S, Guyda H. 1987. Effect of estrogen on the growth hormone response to the alpha-adrenergic agonist in women with menopausal flushing. J Clin Endocrinol Metab 65: 6-10.
33. Umbricht D, Javitt D, Novak G, et al. 1998. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 44: 716-725.
34. Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. 2000. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 57: 1139-1147.
35. Willner P. 1997. The dopamine hypothesis of schizophrenia: current status, future prospects. Int J Clin Psychopharmacol 12: 297-308.